EQ Equillium, Inc.
Equillium, Inc. (EQ) is expected to report earnings on November 12, 2026, after the market close. The consensus earnings estimate is a loss of $0.06 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +16.3% since its last earnings release on August 13, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Equillium, Inc.
Equillium is a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need.
Sector
Healthcare
Industry
Biotechnology